Agirgol, S. Et Al. 2022. Investigation of Cardiovascular Disease and Metabolic Syndrome Risk with Copeptin in Psoriasis Patients: A Case-Control Study. HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI , vol.60, no.3 , 270-275.

Agirgol, S., Akbulut, T. O., Demir, F. T., Cakir, E., Gumus, A., Agirgol, M., ... Turkoglu, Z.(2022). Investigation of Cardiovascular Disease and Metabolic Syndrome Risk with Copeptin in Psoriasis Patients: A Case-Control Study. HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI , vol.60, no.3, 270-275.

Agirgol, Senay Et Al. "Investigation of Cardiovascular Disease and Metabolic Syndrome Risk with Copeptin in Psoriasis Patients: A Case-Control Study," HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI , vol.60, no.3, 270-275, 2022

Agirgol, Senay Et Al. "Investigation of Cardiovascular Disease and Metabolic Syndrome Risk with Copeptin in Psoriasis Patients: A Case-Control Study." HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI , vol.60, no.3, pp.270-275, 2022

Agirgol, S. Et Al. (2022) . "Investigation of Cardiovascular Disease and Metabolic Syndrome Risk with Copeptin in Psoriasis Patients: A Case-Control Study." HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI , vol.60, no.3, pp.270-275.

@article{article, author={Senay Agirgol Et Al. }, title={Investigation of Cardiovascular Disease and Metabolic Syndrome Risk with Copeptin in Psoriasis Patients: A Case-Control Study}, journal={HASEKI TIP BULTENI-MEDICAL BULLETIN OF HASEKI}, year=2022, pages={270-275} }